Free Trial
→ The warning signs most investors see too late (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$55.93
+1.0%		$43.27
$23.00
▼
$59.72
$3.31B1.212.09 million shs1.38 million shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$20.55
-3.9%		$15.88
$8.12
▼
$22.51
$743.77M0.62734,330 shs675,186 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$29.22
+5.9%		$29.33
$23.82
▼
$43.10
$3.52B0.794.14 million shs8.86 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
+0.96%+11.82%+59.16%+14.78%+132.17%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-3.88%+37.64%+39.61%+22.83%+139.23%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+5.95%+8.87%+14.72%-11.96%-28.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$55.93
+1.0%		$43.27
$23.00
▼
$59.72
$3.31B1.212.09 million shs1.38 million shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$20.55
-3.9%		$15.88
$8.12
▼
$22.51
$743.77M0.62734,330 shs675,186 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$29.22
+5.9%		$29.33
$23.82
▼
$43.10
$3.52B0.794.14 million shs8.86 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
+0.96%+11.82%+59.16%+14.78%+132.17%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-3.88%+37.64%+39.61%+22.83%+139.23%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+5.95%+8.87%+14.72%-11.96%-28.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
2.75
Moderate Buy$57.923.55% Upside
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$29.3342.74% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.79
Moderate Buy$93.36219.52% Upside

Current Analyst Ratings Breakdown

Latest DCTH, VKTX, and AXGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C-) ➝ Hold (C+)
11/11/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
11/10/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$32.00 ➝ $36.00
11/9/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$21.00 ➝ $25.00
10/30/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$106.00 ➝ $118.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$52.00 ➝ $56.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$58.00
10/29/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral$34.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$50.00 ➝ $60.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$57.00
10/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$55.00 ➝ $60.00
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$266.93M12.52N/AN/A$8.31 per share6.73
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$85.23M8.39$0.05 per share409.00$3.84 per share5.35
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$15.70M-$0.65N/A430.23N/A-11.96%-5.35%-4.41%N/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$2.70M$0.16128.4462.27N/A6.05%5.56%4.98%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$5.40N/AN/AN/AN/A-117.35%-88.87%N/A

Latest DCTH, VKTX, and AXGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$0.0917$0.17+$0.2617$0.17$25.99 million$35.10 million
10/28/2026Q3 2026
AxoGen, Inc. stock logo
AXGN
AxoGen
$0.1313$0.21+$0.0787$0.04$73.45 million$75.83 million
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.06-$1.55-$0.49-$1.55N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.04
12.02
10.67
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
10.87
8.95
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.43
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.44%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
19.36%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
62259.73 million58.27 millionOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
15634.79 million28.05 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
74127.52 million120.76 millionOptionable

Recent News About These Companies

Viking Therapeutics, Inc. (VKTX) - What Are Researchers Thinking About This Stock?
November 14 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31197348
Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
November 14 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-viking-therapeutics-inc-nasdaq-vktx-stock-now-rated-moderate-buy-by-wall-street-brokerages-2026-11-14/
Viking Therapeutics gains amid report of renewed takeover interest
November 13 at 5:05 PM  |  msn.comhttps://www.msn.com/en-us/money/general/viking-therapeutics-gains-amid-report-of-renewed-takeover-interest/ar-AA2hocZL
Traders Purchase High Volume of Viking Therapeutics Call Options (NASDAQ:VKTX)
November 13 at 2:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-traders-purchase-high-volume-of-viking-therapeutics-call-options-nasdaq-vktx-2026-11-13/
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 5.2% - Here's Why
November 13 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-viking-therapeutics-nasdaq-vktx-stock-price-up-52-heres-why-2026-11-13/
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
November 13 at 10:16 AM  |  zacks.comhttps://www.zacks.com/stock/news/3029374/4-key-stocks-to-watch-across-diabetes-and-obesity-this-awareness-day?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-3029374
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
November 13 at 4:15 AM  |  fool.comhttps://www.fool.com/investing/2026/11/13/predict-10k-invested-viking-therapeutics-obesity/
Viking Therapeutics stock trades at EUR 25.68 on Thursday
November 12 at 11:03 AM  |  ad-hoc-news.deA
Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
November 12 at 6:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-priced-perfection-043400765.html
Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
November 12 at 6:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-vktx-heads-two-091058168.html
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
November 11 at 5:34 PM  |  fool.comhttps://www.fool.com/investing/2026/11/11/eli-lilly-just-raised-its-2026-sales-forecast-to-a/
Viking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
November 11 at 5:00 PM  |  fxempire.comF
Viking Therapeutics stock trades at 26.00 euros Tuesday
November 10, 2026  |  ad-hoc-news.deA
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
November 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3026175/novo-up-4-in-a-month-how-should-investors-approach-the-stock-now?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-3026175
Novo Up 4% in a Month: How Should Investors Approach the Stock Now?
November 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-4-month-investors-approach-125100467.html
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
November 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-two-poster-120500193.html
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
November 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-announces-two-poster-presentations-at-obesityweek-2026-302932884.html
Can You Justify Buying Corcept Stock Today?
November 8, 2026  |  trefis.comT
Here's the 1 Stock I'd Most Want to Buy If the Market Crashes
November 5, 2026  |  fool.comhttps://www.fool.com/investing/2026/11/05/the-1-stock-id-most-want-to-buy-if-the-market/
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
November 4, 2026  |  fool.comhttps://www.fool.com/investing/2026/11/04/viking-therapeutics-trades-xx-below-its-own-35-off/
Viking Therapeutics to Participate at Upcoming Investor Conferences
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-participate-upcoming-investor-213000179.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AxoGen stock logo

AxoGen NASDAQ:AXGN

$55.93 +0.53 (+0.96%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$55.50 -0.43 (-0.77%)
As of 11/13/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$20.55 -0.83 (-3.88%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$20.90 +0.35 (+1.71%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$29.22 +1.64 (+5.95%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$29.17 -0.05 (-0.16%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas